Resverlogix (TSE:RVX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Resverlogix Corp. has extended its secured convertible debenture with Shenzhen Hepalink Pharmaceutical Group, pushing the maturity date to May 13, 2026, while also increasing the interest rate from 12% to 18% and removing Hepalink’s conversion privileges. The amendments, which also include additional reporting requirements and the continuation of normal business operations, are pending approval by the Toronto Stock Exchange and Resverlogix shareholders. This financial restructuring aims to support Resverlogix’s development of epigenetic therapies for chronic diseases.
For further insights into TSE:RVX stock, check out TipRanks’ Stock Analysis page.
